1 After value adjustments on receivables from the Provision of health care Services.
2 Targets for 2016 exclude contributions from acquisitions made in 2015 and 2016.
3 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA.
4 Full-time equivalents.
At the end of 2015, around 2.8 million patients received dialysis. The number of dialysis patients globally showed a growth rate of approximately 6% in 2015. We also expect patient growth to be around 6% per annum going forward. By the year 2020 there will be around 3.8 million patients in the world that need treatment. There are various factors driving this development. The population is getting older, the incidence of risk factors leading to dialysis – obesity, high blood pressure and diabetes – are leading to this patient growth. This development will afford us the opportunity to provide vital and impactful solutions in a market that will grow consistently in coming years.
In the year 2020 we expect to generate 28 billion U.S. Dollars in revenue. Besides the strong growth to be expected from the dialysis service and product business we expect the revenue contribution from the care coordination to increase significantly to 18% in 2020. We foresee this business to grow over-proportional in the years to come – organically as well as through acquisitions.
On the earnings level we expect the earnings per share to show high single digit growth per annum in the same timeframe.
Fresenius Medical Care has retained its global leadership position and we continue to shape the future of the dialysis industry and we will expand into related markets – in order to better coordinate care. Our focus is always – and will always be - on superior quality in both - products and services.